Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Butowski

Showing results (21-30 of 97) with videos related to

Pageof 10
Sort By:
Neuro-Oncology|February 20, 2010
Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomideMei-Yin C Polley, Kathleen R Lamborn, Susan M Chang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Conditional probability of survival in patients with newly diagnosed glioblastomaMei-Yin C Polley, Kathleen R Lamborn, Susan M Chang, et al.
Neuro-Oncology|February 9, 2013
Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiformeJanine M Lupo, Emma Essock-Burns, Annette M Molinaro, et al.
Neuro-Oncology|July 25, 2015
The effects of anti-angiogenic therapy on the formation of radiation-induced microbleeds in normal brain tissue of patients with gliomaJanine M Lupo, Annette M Molinaro, Emma Essock-Burns, et al.
Neuro-Oncology|October 11, 2005
GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trialsSusan M Chang, Sharon L Reynolds, Nicholas Butowski, et al.
Journal of Magnetic Resonance Imaging : JMRI|January 22, 2019
Risk factors of radiotherapy-induced cerebral microbleeds and serial analysis of their size compared with white matter changes: A 7T MRI study in 113 adult patients with brain tumorsMelanie A Morrison, Christopher P Hess, Jennifer L Clarke, et al.
Journal of Neuro-Oncology|March 20, 2017
Chordoid glioma of the third ventricle: report of a rapidly progressive caseAmalie A Erwood, Jose E Velazquez-Vega, Stewart Neill, et al.
Seminars in Oncology|May 6, 2014
Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastomaMario E Lacouture, Mary Elizabeth Davis, Grace Elzinga, et al.
Neuro-Oncology|August 21, 2008
Quality of life in low-grade glioma patients receiving temozolomideRaymond Liu, Karla Solheim, Mei-Yin Polley, et al.
Neuro-Oncology Advances|April 11, 2022
Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143Antonio Omuro, David A Reardon, John H Sampson, et al.
Pageof 10

Showing results (21-30 of 97) with videos related to

Sort By:
Pageof 10
Neuro-Oncology|February 20, 2010
Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomideMei-Yin C Polley, Kathleen R Lamborn, Susan M Chang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Conditional probability of survival in patients with newly diagnosed glioblastomaMei-Yin C Polley, Kathleen R Lamborn, Susan M Chang, et al.
Neuro-Oncology|February 9, 2013
Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiformeJanine M Lupo, Emma Essock-Burns, Annette M Molinaro, et al.
Neuro-Oncology|July 25, 2015
The effects of anti-angiogenic therapy on the formation of radiation-induced microbleeds in normal brain tissue of patients with gliomaJanine M Lupo, Annette M Molinaro, Emma Essock-Burns, et al.
Neuro-Oncology|October 11, 2005
GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trialsSusan M Chang, Sharon L Reynolds, Nicholas Butowski, et al.
Journal of Magnetic Resonance Imaging : JMRI|January 22, 2019
Risk factors of radiotherapy-induced cerebral microbleeds and serial analysis of their size compared with white matter changes: A 7T MRI study in 113 adult patients with brain tumorsMelanie A Morrison, Christopher P Hess, Jennifer L Clarke, et al.
Journal of Neuro-Oncology|March 20, 2017
Chordoid glioma of the third ventricle: report of a rapidly progressive caseAmalie A Erwood, Jose E Velazquez-Vega, Stewart Neill, et al.
Seminars in Oncology|May 6, 2014
Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastomaMario E Lacouture, Mary Elizabeth Davis, Grace Elzinga, et al.
Neuro-Oncology|August 21, 2008
Quality of life in low-grade glioma patients receiving temozolomideRaymond Liu, Karla Solheim, Mei-Yin Polley, et al.
Neuro-Oncology Advances|April 11, 2022
Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143Antonio Omuro, David A Reardon, John H Sampson, et al.
Pageof 10